XCUR: the cashflow

MyFinsight

For the quarter ending 2025-09-30, XCUR had -$3,420K decrease in cash & cash equivalents over the period. -$3,422K in free cash flow.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Net loss	-2,437	389
Depreciation and amortization	82	132
Equity-based compensation	0	1
Amortization of right-of-use asset	-15	104
Change in fair value of contingent consideration	246	295
Gain on early lease termination	0	5,974
Gain on settlement of accounts payables	155	191
Loss from sale or disposal of property and equipment	-4	-86
Other receivable	-23	-1,434
Prepaid expenses and other current assets	127	-169
Other noncurrent assets	-79	734
Accounts payable	-530	303
Accrued expenses	-698	106
Other liabilities	0	0
Net cash used in operating activities	-3,528	-3,880
Property and equipment	-106	320
Proceeds from sale of fixed assets	2	40
Acquisition of gpcr therapeutics usa inc	0	2,090
Net cash used in investing activities	108	-2,370
Proceeds from short-term borrowing	0	0
Proceeds from common stock offering	0	1,600
Net cash provided by provided by financing activities	0	1,600
Net decrease in cash, cash equivalents, and restricted cash	-3,420	-4,650
Cash and cash equivalents at beginning of period	12,508	-
Cash and cash equivalents at end of period	4,438	-

Unit: Thousand (K) dollars